SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about 2026 asco abstract highlights innovent biologics ibi363 pd 1 il 2a bias bispecific fusion protein demonstrates robust survival benefits in long term follow up of poc study in advanced immunotherapy resistant non small cell lung cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer )
Also on site :
- 'Love on the Spectrum' Star Hard Launches New Romance — And Fans Are Shocked by One Trait
- US budget slashing risks losing global scientific edge to China
- Walmart’s Fan-Favorite Zero-Gravity Canopy Lounge Chair Is 50% Off and ‘Perfect for Bird Watching and Stargazing’